Bortezomib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12361 publications
Predictive value of next-generation sequencing-based measurable residual disease quantitative stratification for early disease progression in newly diagnosed multiple myeloma after induction therapy
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 07, 2026
MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.
Journal: Leukemia & lymphoma
Published: September 06, 2026
Refractory Protein-losing Enteropathy Complicated by Cytomegalovirus Enterocolitis after Chemotherapy for Multiple Myeloma: A Fatal Adult Case.
Journal: Internal medicine (Tokyo, Japan)
Published: September 02, 2026
Flavokawain B inhibits ER-associated protein dislocation and reduces infectious Zika virus production.
Journal: Biochemical and biophysical research communications
Published: August 24, 2026
FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.
Journal: Research square
Published: August 20, 2026
Boron-Containing Drug Candidates in Clinical Trials.
Journal: Handbook of experimental pharmacology
Published: August 05, 2026
Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study.
Journal: Annals of medicine
Published: August 03, 2026
A Tale of Two Strategies: Desensitization and Donor-Specific Antibody-Free Transplant in Highly Sensitized Patients.
Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
Published: August 01, 2026
Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management.
Journal: American journal of hematology
Published: July 30, 2026
FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.
Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026
Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database.
Journal: Leukemia & lymphoma
Published: July 27, 2026
Cysteine-mediated bortezomib resistance is governed by α-ketoacid availability.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2026
Last Updated: 09/26/2026